All of Us Research Program
Do you want to change the future of health? The Froedtert & MCW health network is part of the National Institutes of Health All of Us Research Program. It has a simple mission — speed up health research breakthroughs. To do this, All of Us is asking one million people to share their health information. Learn how you can help make a difference by joining the All of Us Research Program.
5 results for "Cancer" and "Prostate and Urologic Cancers" and "Kidney"
Phase 1/1b Study To Evaluate The Safety And Activity Of TTX-030 (Anti-CD39) In Combination With Budigalimab And/Or Chemotherapy In Subjects With Advanced Solid Tumors
This study is being done for the following purposes:
To test the safety of TTX-030 combination therapy in various cancer types
To see if TTX-030 combination therapy works against various cancer types
To see how much TTX-030 combination therapy is in the blood at specific times after dosing and how the body eliminates TTX-030
To see what effects TTX-030 combination therapy has on the body
To test the safety of TTX-030 combination therapy in various cancer types
To see if TTX-030 combination therapy works against various cancer types
To see how much TTX-030 combination therapy is in the blood at specific times after dosing and how the body eliminates TTX-030
To see what effects TTX-030 combination therapy has on the body
Protocol No
TRISHULA-TTX-030-002
A Phase I/II Trial of Pazopanib Alternating with Bevacizumab in Treatment-Naïve Metastatic Clear Cell Renal Cell Carcinoma Patients
Pazopanib Hydrochloride and Bevacizumab in Treating Patients With Previously Untreated Metastatic Kidney Cancer
Protocol No
RPCI-I-191711
Sub Category
Establishment Of A National Biorepository To Advance Studies Of Immune-Related Adverse Events
This study is being done to answer the following questions:
Why do some patients experience serious side effects from immunotherapies, and why do other patients not experience these side effects? How can we identify these patients and prevent, reduce and treat these side effects more effectively?
To answer these questions, it is helpful to have clinical data and samples collected from patients who have experienced these side effects from immunotherapy. For example, by studying blood samples collected before and after side effects occur, researchers can look for markers that may predict ...
Protocol No
ALLIANCE-A151804
PD-Inhibitor (Nivolumab) and Ipilimumab followed by Nivolumab vs. VEGF TKI Cabozantinib with Nivolumab: A Phase III Trial in Metastatic Untreated REnal Cell CancEr [PDIGREE]
This study is being done to answer the following question: Can we prolong life for patients with
advanced kidney cancer, by adding a drug called cabozantinib to another treatment after
receiving the standard treatment?
advanced kidney cancer, by adding a drug called cabozantinib to another treatment after
receiving the standard treatment?
Protocol No
ALLIANCE-A031704-PDIGREE
Sub Category
A Phase 1b, Multicenter Study to Determine the Dose, Safety, Efficacy and Pharmacokinetics of TRK-950 When Used in Combinations with Selected Anti-Cancer Treatment Regimens in Patients with Selected Advanced Solid Tumors
A Study of TRK-950 in Combinations With Anti-Cancer Treatment Regimens in Patients With Advanced Solid Tumors
Protocol No
TORAY-950P1V02